Research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic rsearch, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
The organizers of the Institute seminars are happy to start the autumn 2014 season with a very interesting external speaker: Larry W. Kwak, Chair, Lymphoma/Myeloma and director of the Center for Cancer Immunology Research at MD Anderson Cancer Center.
Internationally recognized for his 20-year commitment to the science of cancer vaccines, Dr. Kwak developed Biovest's BiovaxID® personalized lymphoma cancer vaccine while at the U.S. National Cancer Institute.
In 2010, Dr. Kwak was the first active MD Anderson faculty member to be named to TIME Magazine's "TIME 100" annual list of the 100 most influential people in the world for his contributions to the advancement of cancer vaccines.
Time and place: Auditorium, Wednesday 27th, 12-13.
Professor Øyvind S. Bruland, head of the Sarcoma group at the from the Department of Oncology at Oslo University Hospital, has together with Roy Hartwig Larsen won the University of Oslo Innovation Prize for 2014.
Bruland and his research has in this connection been thoroughly presented in UiO's web newspaper "Uniforum" and in UiO's research magazine "Apollon".
Jonas Paulsen at the Institute for Cancer Genetics and Informatics at Oslo University Hospital is first author on an article recently published in Nucleic Acids Research (NAR, journal impact factor 8.8), entitled “A statistical model of ChIA-PET data for accurate detection of chromatin 3D interactions”. In their recent paper, the authors have developed a sophisticated statistical model to accurately identify three-dimensional (3D) interactions between distal regulatory elements in the genome, based on ChIA-PET technology.
ChIA-PET is a novel method to identify 3D interactions, where physical contacts between regions bound by a specific protein are quantified using next-generation sequencing. Such interactions are vital for the functioning of the regulatory machinery that govern the proliferation and differentiation of cells.
Lina Herstad from the Norwegian National Advisory Unit on Women's Health at Woman and Children' Division at Oslo University Hospital is first author on an article recently published in BJOG, entitled "Maternal age and emergency operative deliveries at term: a population-based registry study among low-risk primiparous women."
The study used a sample of 169,583 low risk, first-time mothers in Norway to examine the association between maternal age and emergency operative delivery. The results suggest that an increased risk of emergency operative delivery is linked with increasing maternal age.
The study has attracted considerable attention, and the findings are discussed on several popular science international web sites, such as Science Daily and Science World Report.
The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".
For the month of July 2014, this honour went to Erik Fosse from the Intervention Centre at the Division of Diagnostics and Intervention, Oslo University Hospital.
Ola Myklebost from the Department of Tumor Biology and Anne-Lise Børresen-Dale co-author an article published in Science (journal impact factor 31) Aug 1st, entitled "Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes".
This article described the detailed analysis of rearrangements involving L1 retrotransposons in multiple cancer types, including breast and bone cancer, based on sub studies within the framework of the International Cancer genome Consortium. Børresen-Dale’s group is a partner in the Breast Cancer Consortium, and that of Ola Myklebost in the Bone Cancer Group.
Aug 19, 2014
Selected latest publications
Journ. Impact factor > 8 First or last author from Oslo University Hospital
Genome-wide DNA methylation profiles in progression to
Genome Biol, 15 (8), 435 (in press)
Bariatric surgery versus intensive medical therapy for diabetes
N Engl J Med, 371 (7), 681
More selected publications